Key result
Elevated plasma NT-proBNP (>243 pg/ml) was a strong independent predictor of 30-day major adverse clinical outcomes (OR 3.59) in patients with ST-segment elevated acute myocardial infarction undergoing primary PCI.
Why the study?
Does elevated NT-proBNP predict 30-day major adverse clinical outcomes in patients with ST-segment elevated AMI undergoing primary PCI?
Cohort (n=242)
No
Does elevated NT-proBNP predict 30-day major adverse clinical outcomes in patients with ST-segment elevated AMI undergoing primary PCI?
Odds Ratio: 3.59 (95% CI 1.85–7)
p-value: p=0.0002
Elevated plasma NT-proBNP on admission is a strong independent predictor of 30-day major adverse clinical outcomes and mortality in patients with STEMI undergoing primary PCI.
No takes yet. Share an insight, caveat, or question.
May aid risk stratification in STEMI after primary PCI; leaves open whether NT-proBNP-guided interventions improve outcomes.
Wu et al. (2006) conducted a cohort in ST-segment elevated acute myocardial infarction (AMI) (n=242). Elevated NT-proBNP (>243 pg/ml) vs. NT-proBNP ≤243 pg/ml was evaluated on 30-day composite major adverse clinical outcomes (MACO) including advanced Killip score ≥3, advanced CHF, or 30-day death (OR 3.59, 95% CI 1.85-7.00, p=0.0002). Elevated plasma NT-proBNP (>243 pg/ml) was a strong independent predictor of 30-day major adverse clinical outcomes (OR 3.59) in patients with ST-segment elevated acute myocardial infarction undergoing primary PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: